SCHEMBL246534

SCHEMBL246534

Nc1cc(N2CCOCC2)ncc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
CYP1A2 P05177 3/20 0.44
MAPT P10636 3/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2C9 P11712 2/20 0.44
MAPK1 P28482 1/20 0.44
CYP2D6 P10635 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
PIK3CA P42336 4/20 0.43
MAP3K12 Q12852 1/20 0.43
TSHR P16473 1/20 0.43
ADK P55263 1/20 0.43
CNR2 P34972 1/20 0.42
SMPD3 Q9NY59 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KMO O15229 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15543262 0.84 ALDH1A1 (0.48) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL29745217 0.84 ALDH1A1 (0.48) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL14910307 0.80 KDM4E (0.47) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL245708 0.80 PIK3CA (0.47) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL21246773 0.80 CNR2 (0.52) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL1460126 0.80 ALDH1A1 (0.58) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL1912048 0.80 ALDH1A1 (0.58) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL31195982 0.80 CNR2 (0.46) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL9013757 0.78 ALDH1A1 (0.43) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9
SCHEMBL29300851 0.77 ALDH1A1 (0.44) ALDH1A1CYP1A2MAPTCYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 ALDH1A1 3735/4885CYP1A2 2019/4885MAPT 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.